[Dupilumab-Associated Healing of Alopecia Areata in an Atopic Dermatitis Patient]. / Dupilumab-asssoziierte Abheilung einer Alopecia areata bei Atopischem Ekzem.

HISTORY AND FINDINGS: A 25-year-old female patient was treated with the anti-IL-4/IL-13 receptor antibody Dupilumab due to severe atopic dermatitis (AD). In addition, the patient had been suffering from alopecia areata (AA) for 5 years. EXAMINATION AND DIAGNOSIS: At first presentation a severe AD (Scoring Atopic Dermatitis [SCORAD] 76.0; Eczema Area and Severity Index [EASI] 37.4) with a total-IgE of 1108 kU/l and an Alopecia areata was observed. THERAPY AND COURSE: One year ago, treatment with the anti-IL-4/IL-13 receptor antibody Dupilumab was initiated. After 5 months, there was a marked improvement in AD (SCORAD 32.2; EASI 3.8) and increased hair growth. After 11 months, the AE remained stably improved (SCORAD 27,0; EASI 2,7) and almost all hairs had regrown. CONCLUSIONS: The comorbidity between AD and AA is known. The influence of dupilumab on AA is a new finding. The present case report supports the hypothesis that inhibition of IL-4 and IL-13 signalling pathways has a real and long-term effect on hair growth in AA. In patients with AD and concomitant AA, a positive effect on comorbidity AA can also be expected.